Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Vanda (VNDA) today and set a price target of $43. The company’s shares closed on Friday at $26.24.
According to TipRanks.com, Duncan is a 1-star analyst with an average return of -2.3% and a 41.3% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vanda with a $40.83 average price target, representing a 55.6% upside. In a report issued on December 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $36 price target.
.
See today’s analyst top recommended stocks >>
Vanda’s market cap is currently $1.37B and has a P/E ratio of 108.83. The company has a Price to Book ratio of 5.26.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
